Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer.
chitinase-3-like protein 1
colorectal cancer
heat shock protein 60
insulin-like growth factor binding protein 2
serum biomarker
survival
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
02
12
2018
accepted:
12
07
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
4
12
2019
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is the second leading tumor diagnosis in women and men in the Czech Republic. Patient outcome depends on tumor stage at the time of diagnosis and, in metastatic disease, on the localization and extent of distant metastases. The early detection of metastatic liver disease is an important indication for liver surgery. Therefore, novel biomarkers are urgently required. Serum samples were collected from 97 patients with histologically confirmed metastatic CRC at the time of diagnosis or at the time of progression during palliative treatment, and 79 samples from healthy controls. All patients exhibited adequate liver and renal function and signed informed consent was obtained from all patients included in the current study. The serum levels of Heat shock protein 60 (HSP60), Chitinase-3-like protein 1 (CHI3L1) and Insulin-like growth factor binding protein 2 (IGFBP-2) were measured using immunochemistry. The serum levels of HSP60, CHI3L1 and IGFBP-2 were significantly higher in patients with CRC compared with healthy controls. When compared with carcinoembryonic antigen (CEA), HSP60 exhibited the same sensitivity and specificity, while CHI3L1 and IGFBP-2 exhibited decreased sensitivity. Additionally, the serum levels of HSP60 and IGFBP-2 were indicated to be correlated with the presence of liver metastases, which is in contrast to CEA and Cancer antigen 19-9 (CA19-9). Patients with higher HSP60 and IGFBP-2 levels exhibited a significantly worse survival (P<0.001 and 0.007, respectively). The results of the current study indicate HSP60 to be an effective biomarker in patients with metastatic CRC, with it exhibiting an equal sensitivity to CEA. Additionally, HSP60 and IGFBP-2 levels also strongly correlated with extension of liver metastases and exhibited a prognostic value that contrasted that of CEA.
Identifiants
pubmed: 31788106
doi: 10.3892/ol.2019.10925
pii: OL-0-0-10925
pmc: PMC6864964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6284-6292Informations de copyright
Copyright © 2019, Spandidos Publications.
Références
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):552-61
pubmed: 21441812
Mol Cancer Ther. 2011 May;10(5):742-51
pubmed: 21357475
Biol Rev Camb Philos Soc. 2013 Nov;88(4):955-87
pubmed: 23551966
World J Gastroenterol. 2009 Nov 14;15(42):5249-59
pubmed: 19908331
Urology. 2010 Oct;76(4):1017.e1-6
pubmed: 20708221
J Korean Med Sci. 1999 Aug;14(4):401-4
pubmed: 10485619
Endocr Rev. 2009 Aug;30(5):417-37
pubmed: 19477944
PLoS One. 2011;6(11):e28200
pubmed: 22140545
Eur J Histochem. 2003;47(2):105-10
pubmed: 12777205
J Mol Endocrinol. 2004 Jun;32(3):859-68
pubmed: 15171717
J Clin Oncol. 2009 Feb 1;27(4):572-8
pubmed: 19075264
J Histochem Cytochem. 2007 Dec;55(12):1213-28
pubmed: 17712177
Oncogene. 2012 Jun 28;31(26):3111-23
pubmed: 22056877
Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):621-6
pubmed: 25597749
Neoplasma. 2015;62(3):470-7
pubmed: 25866228
Cancer Biol Ther. 2006 Jul;5(7):714-20
pubmed: 16861898
J Histochem Cytochem. 2012 Mar;60(3):188-204
pubmed: 22140133
Bull Exp Biol Med. 2014 Mar;156(5):684-8
pubmed: 24770758
Future Oncol. 2009 Sep;5(7):1065-82
pubmed: 19792974
Annu Rev Biochem. 1993;62:349-84
pubmed: 8102520
Annu Rev Physiol. 2011;73:479-501
pubmed: 21054166
J Clin Endocrinol Metab. 2010 Apr;95(4):1717-25
pubmed: 20157191
Cytokine Growth Factor Rev. 1997 Mar;8(1):45-62
pubmed: 9174662
Cell Stress Chaperones. 2014 May;19(3):343-53
pubmed: 24057177
Oncotarget. 2017 Jul 5;8(33):54978-54992
pubmed: 28903396
Nat Rev Cancer. 2004 Jul;4(7):505-18
pubmed: 15229476
FEBS J. 2011 Dec;278(24):4845-59
pubmed: 21973086
Cancer. 2002 Jul 15;95(2):267-74
pubmed: 12124825
Med Oncol. 2014 Aug;31(8):85
pubmed: 24996799
Proteomics Clin Appl. 2007 Mar;1(3):336-42
pubmed: 21136683
Klin Onkol. 2014;27(6):406-23
pubmed: 25493580
J Clin Endocrinol Metab. 1993 Apr;76(4):1031-5
pubmed: 7682560
J Exp Med. 2009 May 11;206(5):1149-66
pubmed: 19414556
Circulation. 2002 Feb 26;105(8):1012-7
pubmed: 11864934
J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5
pubmed: 15467030
BMC Cancer. 2005 Oct 28;5:139
pubmed: 16253146
Cell Stress Chaperones. 2010 Nov;15(6):877-84
pubmed: 20390473
Front Physiol. 2013 May 28;4:122
pubmed: 23755018
Clin Immunol. 2011 Sep;140(3):268-75
pubmed: 21546314
Electrophoresis. 1997 Dec;18(15):2832-41
pubmed: 9504817
Clin Chem. 2010 Oct;56(10):1580-91
pubmed: 20798353
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Natl Cancer Inst. 1999 Jul 7;91(13):1147-54
pubmed: 10393723
Br J Cancer. 1999 Mar;79(9-10):1494-9
pubmed: 10188896
Br J Cancer. 2000 Nov;83(10):1344-50
pubmed: 11044360
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
pubmed: 10995803